Stockscreener 앱 받기
32.20
0.53%
0.17
전일 마감가:
$32.03
열려 있는:
$31.99
하루 거래량:
3.44M
Relative Volume:
0.77
시가총액:
$13.95B
수익:
$2.27B
순이익/손실:
$1.15B
주가수익비율:
12.63
EPS:
2.55
순현금흐름:
$2.80B
1주 성능:
-1.23%
1개월 성능:
-4.62%
6개월 성능:
+19.48%
1년 성능:
+14.55%
1일 변동 폭
$31.84
$32.30
1주일 범위
$31.58
$32.73
52주 변동 폭
$24.05
$34.20
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
RPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
32.20 | 13.95B | 2.27B | 1.15B | 2.80B | 2.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Royalty Pharma plc (NASDAQ:RPRX) to Issue $0.22 Quarterly Dividend - MarketBeat
Brokerages Set Royalty Pharma plc (NASDAQ:RPRX) Price Target at $42.50 - MarketBeat
Cerity Partners LLC Sells 15,537 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Canada Pension Plan Investment Board Buys 39,070 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Guggenheim Capital LLC Sells 82,768 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Adage Capital Partners GP L.L.C. Raises Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
GMT Capital Corp Grows Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Barclays PLC Raises Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Walleye Capital LLC Buys Shares of 25,124 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Dark Forest Capital Management LP Has $3.42 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Jump Financial LLC Makes New $2.09 Million Investment in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Invesco Ltd. Raises Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Bridgewater Associates LP Acquires New Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma PLC (RPRX) Surged Following an Acquisition Announcement - Insider Monkey
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Synovus Financial Corp - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Ontario Teachers Pension Plan Board - MarketBeat
Regal Investment Advisors LLC Has $452,000 Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Evergreen Capital Management LLC Has $2.75 Million Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Raymond James Financial Inc. Invests $19.99 Million in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Sterling Capital Management LLC Grows Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Treasurer of the State of North Carolina Sells 10,837 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Keeps Dividend at $0.22 A Share, Payable June 10 to Shareholders of Record May 16 - marketscreener.com
Royalty Pharma plc Announces Second Quarter 2025 Dividend Payment of $0.22 per Class A Ordinary Share - Nasdaq
Royalty Pharma Declares Second Quarter 2025 Dividend - The Manila Times
Bank of Montreal Can Has $3.69 Million Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
BofA Adjusts Price Target on Royalty Pharma to $42 From $41 - marketscreener.com
Portolan Capital Management LLC Purchases 173,721 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
(RPRX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025 - The Manila Times
Royalty Pharma plc to Announce Q1 2025 Financial Results on May 8, 2025 - Nasdaq
Royalty Pharma Schedules Critical Q1 2025 Earnings Release: Key Details for Investors - Stock Titan
Legal & General Group Plc Has $67.19 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
APG Asset Management N.V. Grows Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Aviva PLC Boosts Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
APG Asset Management US Inc. Takes $201,000 Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by CenterBook Partners LP - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Fmr LLC - MarketBeat
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.06%
36.06%
자본화:
|
볼륨(24시간):